Last reviewed · How we verify
Remifentanil infusion
Remifentanil infusion is a Small molecule drug developed by University of California, San Francisco. It is currently FDA-approved. Also known as: Target-controlled infusion (TCI) of remifentanil, Remifentanil hydrochloride, Remifentanil, ultiva.
Remifentanil is a small molecule that acts as a mu opioid receptor agonist, classified as an agonist. It is used in clinical settings for conditions such as pain threshold, surgery, postoperative pain, intravenous anesthesia, and aging problems, often administered through infusion.
At a glance
| Generic name | Remifentanil infusion |
|---|---|
| Also known as | Target-controlled infusion (TCI) of remifentanil, Remifentanil hydrochloride, Remifentanil, ultiva, Ultiva® |
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Comparison of Target-Controlled and Manual Total Intravenous Anesthesia in Supratentorial Surgery (NA)
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Effect of Titrated Administration of Ciprofol on Perioperative Hypotension in Elderly Patients Undergoing Laparoscopic Abdominal Surgery: A Randomized Controlled Trial (NA)
- Anesthesia Maintenance With Target-controlled Infusion of Propofol and Remifentanil at Fixed Ratio (PHASE4)
- A Study on Median Effective Concentration of Ciprofol Combined With Remifentanil Via Target-controlled Infusion for Inhibiting Tracheal Intubation Stimulation Under qNOX Index Monitoring (NA)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remifentanil infusion CI brief — competitive landscape report
- Remifentanil infusion updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI
Frequently asked questions about Remifentanil infusion
What is Remifentanil infusion?
Who makes Remifentanil infusion?
Is Remifentanil infusion also known as anything else?
What development phase is Remifentanil infusion in?
Related
- Manufacturer: University of California, San Francisco — full pipeline
- Also known as: Target-controlled infusion (TCI) of remifentanil, Remifentanil hydrochloride, Remifentanil, ultiva, Ultiva®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing